Dreyling, A. “Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports (formerly Haematologica Reports), vol. 2, no. 5, June 2009, doi:10.4081/hmr.v2i5.749.